Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily

NCT00496470 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00496470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00496470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2007
Completion date
June 30, 2008
Enrollment
660 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, copd